Table 2.

Incidences of LA— stratified by age, CLD and CKD

Exposure	Person‐years	N. of events	Crude incidence [95% CI]	Age‐sex adjusted incidence [95% CI]*	Adjusted rate ratio [95% CI] *
Target population	504 169	30	5.95 [4.16–8.51]
Metformin users	133 614	7	5.24 [2.50–10.99]	5.80 [2.68–12.57]	1.00 [0.41–2.47]
Non metformin users	370 555	23	6.21 [4.12–9.34]	5.78 [3.73–8.96]	Ref
Age <65 y	192 796	7	3.63 [1.73–7.62]	3.60 [2.50–5.30]
Metformin users	70 218	2	2.85 [0.71–11.39]	2.75 [0.62–12.13]	0.70 [0.14–3.57]
Non Metformin users	122 578	5	4.08 [1.70–9.80]	3.91 [1.59–9.62]	Ref
Age 65–74 y	166 470	10	6.01 [3.23–11.16]	5.90 [4.30–8.20]
Metformin users	42 162	1	2.37 [0.33–16.84]	2.30 [0.29–17.91]	0.33 [0.04–2.54]
Non Metformin users	124 309	9	7.24 [3.77–13.91]	6.88 [3.53–13.44]	Ref
Age 75 y–	144 902	13	8.97 [5.21–15.45]	8.80 [6.60–11.80]
Metformin users	21 234	4	18.84 [7.07–50.19]	18.75 [7.11–49.45]	2.58 [0.80–8.34]
Non Metformin users	123 668	9	7.28 [3.79–13.99]	7.27 [3.76–14.07]	Ref
Disease subgroup
Patients without CLD
Metformin users	103 550	5	4.83 [2.01–11.60]	5.25 [2.16–12.75]	1.09 [0.39–3.15]
Non Metformin users	285 830	16	5.60 [3.43–9.14]	4.80 [2.68–8.59]	Ref
Patients with CLD
Metformin users	30 064	2	6.65 [1.66–26.60]	4.46 [1.06–18.82]	0.86 [0.16–4.69]
Non Metformin users	84 725	7	8.26 [3.94–17.33]	5.18 [1.58–16.97]	Ref
Patients without CKD
Metformin users	115 212	3	2.60 [0.84–8.07]	2.81 [ 0.84–9.37]	1.52 [0.37–6.19]
Non Metformin users	305 164	6	1.97 [0.88–4.38]	1.85 [ 0.83–4.11]	Ref
Patients with CKD
Metformin users	18 402	4	21.74 [8.16–57.92]	23.59 [ 8.68–64.12]	0.98 [0.30–3.23]
Non Metformin users	65 391	17	26.00 [16.16–41.82]	23.96 [14.01–40.98]	Ref

Data was shown as 100 000 person‐years.

^* Poisson regression was adjusted for age groups (18–64, 65–74, 75–) and gender (female, male).